Vnitr Lek 2009, 55(3):263-266

Blood platelets metabolic and activation processes and options for their inhibition

M. Pecka*, J. Malý
Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, a Katedra interních oborů Lékařské fakulty UK Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

A range of activation processes and confirmatory and metabolic changes take place in blood platelets following their activation. The paper discusses some of the blood platelet activation steps and describes the specific processes that take place on this level. Furthermore, the points at which it is possible to actively interfere with the blood platelet metabolism or activation processes are described. Antiplatelet treatment focuses on these points and there are efforts to identify active substances that either inhibit access to certain receptors or targets or, alternatively, inhibit the enzymes participating in these processes.

Keywords: blood platelet; activation; adhesion; aggregation; inhibition; blockade; antiplatelet treatment

Received: February 9, 2009; Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pecka M, Malý J. Blood platelets metabolic and activation processes and options for their inhibition. Vnitr Lek. 2009;55(3):263-266.
Download citation

References

  1. Badimon L, Badimon JJ. Interaction of platelet activation and coagulation. In: Fuster V, Topol EJ (eds). Atherosclerosis and coronary artery disease. Philadelphia: Lippincott - Raven Publishers 1996: 639-656.
  2. Jackson SP, Nesbitt, WS, Kulkarni S. Signaling events underlying thrombus formation. J Thrombos Haemostas 2003; 1: 1602-1612. Go to original source... Go to PubMed...
  3. Ruggeri Z. The role of von Willebrand factor in trombus formation. Thromb Res 2007; 120: 5-9. Go to original source... Go to PubMed...
  4. Yap CL, Anderson KE, Hughan SC et al. Essential role for phosphoinositide 3-kinase in shear dependent signaling between platelet glycoprotein Ib/V/IX and integrin αIIbβIII. Blood 2002; 99: 151-158. Go to original source... Go to PubMed...
  5. Gibbons JM. Platelet adhesion signaling and the regulation of thrombus formation. J Cell Sci 2004; 117: 3415-3425. Go to original source... Go to PubMed...
  6. Dalen JE. An apple a day or an aspirin a day. Arch Intern Med 1991; 151: 1066-1069. Go to original source...
  7. McKee SA, Sane DC, Dellargyris EN. Aspirin resistance in cardiovascular diseases: A review of prevalence, mechanisms and clinical significance. Thromb Haemost 2002; 88: 711-715. Go to original source... Go to PubMed...
  8. Samama MM, Elalamy I. Aspirine et hémostase. Rev Méd Interne 2000; 21: 27-34. Go to original source... Go to PubMed...
  9. Awtry HA, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218. Go to original source... Go to PubMed...
  10. Hilmerová J, Filipovský J. Klinický význam aspirinové rezistence. Vnitř Lék 2004; 50: 462-469. Go to PubMed...
  11. Vane JR, Bakhle YS, Botting RM. Cyklooxygenases 1 a 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120. Go to original source... Go to PubMed...
  12. Patrono C, Coller B, Dalen JE et al. Platelet-Active Drugs. The relationship among dose, effectiveness and side effects. Chest 2001; 119: 39-63. Go to original source... Go to PubMed...
  13. Gollapudi RR, Teirstein PS, Stevenson DD et al. Aspirin sensitivity. Implications for Patiens with coronary arterydisease. JAMA 2004; 292: 3017-3023. Go to original source... Go to PubMed...
  14. Altman R, Luciardi HL, Muntaner J et al. The antitrombotic profile of Aspirin. Aspirin resistence, or simply failure? Thromb Haemost 2001; 2: 1. Go to original source...
  15. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-232. Go to original source... Go to PubMed...
  16. Kahn ML, Nakanishi-Matsui M, Shapiro MJ et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-887. Go to original source... Go to PubMed...
  17. Gaspoz JM, Coxson PG, Goldman PA et al. Cost-effectivenes of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346: 1800-1806. Go to original source... Go to PubMed...
  18. Vojáček J. Inhibitory destičkových glykoproteinových receptorů typu IIb/IIIa. Remedia 2003; 13: 84-92.
  19. Vojáček J, Malý M, Hraboš V et al. Hladina tkáňového faktoru, inhibitoru tkáňového faktoru a solubilního P-selektinu u nemocných s akutním koronárním syndromem. Cor Vasa 2002; 44: 148-151.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.